Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship

被引：1
|
作者：
Rubboli, Andrea [1 ]
Verheugt, Freek W. A. [2 ]
机构：
[1] Osped Maggiore Bologna, Lab Intervent Cardiol, Div Cardiol, Largo Nigrisoli 2, I-40133 Bologna, Italy
[2] OLVG, Heartctr, Dept Cardiol, Oosterpk 9, NL-1091 AC Amsterdam, Netherlands
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2016年 / 223卷
关键词：
Non-vitamin K-antagonist oral anticoagulants; Oral anticoagulation; ATRIAL-FIBRILLATION; RENAL-FUNCTION; WARFARIN; RIVAROXABAN; DABIGATRAN; APIXABAN; EFFICACY; SAFETY;
D O I：
10.1016/j.ijcard.2016.08.207
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：519 / 520
页数：2
相关论文
共 50 条
  • [31] Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis
    Wulamiding, Kaisaier
    Xu, Zixuan
    Chen, Yili
    He, Jiangui
    Wu, Zexuan
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [32] Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function
    Lee, So-Ryoung
    Choi, Eue-Keun
    Han, Kyung-Do
    Jung, Jin-Hyung
    Cha, Myung-Jin
    Oh, Seil
    Lip, Gregory Y. H.
    STROKE, 2019, 50 (06) : 1480 - 1489
  • [33] Non-vitamin K antagonist oral anticoagulants and sport
    Romano, Silvio
    Salustri, Elisa
    Robles, Antonio G.
    Calo, Leonardo
    Penco, Maria
    Sciarra, Luigi
    MINERVA CARDIOANGIOLOGICA, 2020, 68 (02): : 98 - 109
  • [34] The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly
    Patti, Giuseppe
    Cavallari, Ilaria
    Hanon, Olivier
    De Caterina, Raffaele
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 265 : 118 - 124
  • [35] Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
    Giugliano, Robert P.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : A1 - A10
  • [36] The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation A PRISMA-compliant article
    Liu, Xuyang
    Huang, Manxiang
    Ye, Caisheng
    Zeng, Junquan
    Zeng, Changai
    Ma, Jianyong
    MEDICINE, 2020, 99 (27)
  • [37] Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority
    Riva, Nicoletta
    Ageno, Walter
    BLOOD TRANSFUSION, 2015, 13 (02) : 181 - 183
  • [38] Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies
    Anghel, Larisa
    Sascau, Radu
    Trifan, Anca
    Zota, Ioana Madalina
    Statescu, Cristian
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [39] A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin
    Cangemi, David J.
    Krill, Timothy
    Weideman, Rick
    Cipher, Daisha J.
    Spechler, Stuart J.
    Feagins, Linda A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (05) : 734 - 739
  • [40] Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis
    Renda, Giulia
    Ricci, Fabrizio
    De Caterina, Raffaele
    AMERICAN JOURNAL OF MEDICINE, 2017, 130 (04) : 457 - 461
12345